Treatment Approach for Refractory Evans Syndrome

Initial Assessment and Definition

• Before confirming refractoriness, it's essential to re-evaluate the primary diagnosis, exclude other etiologies, check treatment appropriateness, assess patient compliance, and distinguish active disease from irreversible damage, as recommended by Nature Reviews Rheumatology 1

Treatment Algorithm for Refractory Evans Syndrome

Alternative Second-Line Options

• Thrombopoietin receptor agonists (eltrombopag, romiplostim) are recommended for chronic immune thrombocytopenia component, especially in cases with previous severe infections, with response rates of 70-81% for eltrombopag and 79-88% for romiplostim, according to Blood 2
• Combination chemotherapy may be effective in some chronic refractory cases, using cyclophosphamide, prednisone, vincristine, plus either azathioprine or etoposide, as reported in Blood 2

Third-Line and Beyond Options

• Plasma exchange can be considered in severe cases not responding to other therapies, as suggested by Nature Reviews Rheumatology 1 and American Journal of Kidney Diseases 3
• Hematopoietic stem cell transplantation can be considered in cases unresponsive to all immunosuppressive agents, though this carries significant risks, according to Blood 2
• Campath-1H (alemtuzumab) is an alternative for severe, refractory cases but requires prolonged antifungal, antibacterial, and antiviral prophylaxis due to severe immunosuppression, as reported in Blood 2